Literature DB >> 20461951

[Obesity and gastroesophageal reflux disease].

Salvatore De Marco1, Carlo Passaglia.   

Abstract

Obesity, defined as body mass index >30, and gastroesophageal reflux disease show a prevalence of 30%, and 15-20% respectively, in adults in western countries. Obesity increase prevalence of gastroesophageal reflux disease, through difference physiopathological mechanism, that involve esophageal and gastric motility, sexual hormones, dietary habits and drugs intake, presence of hiatal hernia, elevated intra-abdominal pressure. Several surgical treatment options are avalaible in obese patients, which can be divided into restrictive (acting through reduction of gastric volume), or malabsorptive techniques (acting through functional shortening of digestive tract), or a combination of both. Type of surgical approach influences gastroesophageal reflux disease outcome in obese patients with pre-existing symptoms; Roux-en-Y gastric bypass probably represents the best option for these, eligible for bariatric surgery.

Entities:  

Mesh:

Year:  2010        PMID: 20461951

Source DB:  PubMed          Journal:  Recenti Prog Med        ISSN: 0034-1193


  3 in total

1.  Scintigraphic methods to evaluate alterations of gastric and esophageal functions in female obesity.

Authors:  Ozgür Omür; Mehmet Erdoğan; Hayal Ozkılıç; Candeğer Yılmaz
Journal:  Mol Imaging Radionucl Ther       Date:  2014-02-05

2.  Gastroesophageal reflux disease prevalence among school teachers of Saudi Arabia and its impact on their daily life activities.

Authors:  Abdulrahman Mohammed Altwigry; Majed Saud Almutairi; Masood Ahmed
Journal:  Int J Health Sci (Qassim)       Date:  2017 Apr-Jun

3.  Impact of the halitosis on QoL in overweight and obese patients: Based on six years of experience in two centers in sulaimani governorate, Kurdistan Region/Iraq, and case series study.

Authors:  Hiwa Omer Ahmed; Sherko Saeed F Zmnako; Zanyar Mustafa Amin; Rajan Fuad Ezzat; Aram Kakarash; Shahen H Omer; Hawbash Othman; Bawan Sherif
Journal:  Ann Med Surg (Lond)       Date:  2019-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.